UK engineering firm Doosan Babcock has been awarded a contract by GlaxoSmithKline (GSK) for a new active pharmaceutical ingredients (API) facility at the GSK Montrose site in Angus, Scotland. The contract, worth around £25 million ($38 million), will see Doosan Babcock work with GSK to design, build, and install the API facility which, on completion, will produce active ingredients for three of GSK's new medicines for the management of respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD).

A team of 40 Doosan Babcock engineers are already at work on the Montrose project, having completed the initial feed study undertaken by Doosan Babcock in 2014. GSK plans to recruit a further 25 employees at the facility once it is completed in the summer of 2016.

Source: Doosan Babcock